Pharmaceutical power
By Solita Collas-Monsod
Inquirer
Last updated 02:21am (Mla time) 08/11/2007
MANILA, Philippines -- It is a reflection of the power of the multinational pharmaceutical companies in the Philippines that almost 20 years after the passage of the Generics Law in the Philippines, generic products account for less than 5 percent of drugs and medicines sold in the country. This is in contrast with what is happening in the United States, which passed a similar law only four years before we did, but where generics now account for 60 percent of drug sales.
And this state of affairs persists even in the face of incontrovertible evidence that the prices of commonly used, branded medicines sold here can be as much as 10 times higher than the same medicines sold in other Asian countries and, sometimes, even higher than they are sold in industrial countries like the United States and Canada. We’re talking not only about the same medicine but the same manufacturer, mind you.
It is also a reflection of the power of the multinational pharmaceutical companies in the Philippines that Sen. Mar Roxas has been unsuccessful so far in pushing for his bill (filed in 2005) that would result in cheaper medicines for the Filipino people.
Of course, let’s face it, these multinationals would not be able to exercise such power without the cooperation of Filipinos themselves, in particular some members of the medical profession and some members of Congress. The American multinationals also have in their arsenal some very high-priced lobbyists, including former high-ranking US Embassy officials.
All these require a lot of money -- either directly in cash, or converted to in-kind contributions (financing hotel and travel expenditures, underwriting seminars and conferences) or for lawsuits and temporary restraining orders when all else fails. Moreover, they don’t seem to hesitate to apply outright intimidation techniques; threats to withhold supplies to drugstores that do not “cooperate” with them have also been used.
A few examples of how the pharmaceutical power is exercised:
That the Generics Law of 1988 was passed at all is not for want of trying on the part of the pharmaceutical industry to block it, including the use of the Philippine Medical Association in the fight, but because of the perseverance of Alran Bengzon, who was health secretary at the time.
One of the Trojan horses that got stuck in it was allowing doctors to prescribe their choice of branded medicine (a practice not allowed in US laws) together with the generic prescription. And this is what most doctors in private practice in the Philippines do. That they seem to have very cozy relationships with drug companies is perhaps due to the fact that they get a lot of freebies, which are ultimately paid for by the Filipino consumer: 20 percent of the price paid by Filipinos for their medicine is used by pharmaceuticals to pay for “promotions,” i.e., expenses incurred for sponsoring doctors’ foreign trips, seminars, conferences, as well as ads and other endorsements.
Then there was the attempt 10 years later, even as the generics law was perceived to have fallen by the wayside, of then-secretary of trade and industry Mar Roxas to initiate “parallel importation,” that is, buying branded, off-patent (i.e., the patents held by the drug companies had already expired) medicines from India that were selling there at a fraction of Philippine prices. Roxas was reacting to studies which showed how Filipinos were paying much higher prices for essential medicines than their Asian and Western counterparts.
Ang local auto industry,oligopoly. Ang local oil industry, oligopoly. pati ba naman gamot.......hayyyy........





Reply With Quote

(Pero, masaya raw ang mga tao rito....
